COVID-19 Seroprevalence in Pregnant Women and Blood Donors

Centre Hospitalier Universitaire de Besancon797 enrolled

Overview

The study aims to measure the SARS-CoV-2 seroprevalence (ie. the proportion of people with antibodies against the virus) in pregnant women and blood donors in an administrative area of France, and to determine whether these measures are representative of the general population.

Study Type

OBSERVATIONAL

Enrollment

797

Conditions

COVID-19 Respiratory Infection

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Pregnant women * Adult female * Admitted to hospital for live birth * Informed consent * Affiliated to the French social security health insurance scheme * Blood donors * Adult male or female * Qualified for whole blood donation (up to 70 years old in France) * Informed consent * Affiliated to the French social security health insurance scheme Exclusion Criteria: * Legal incapacity or limited legal capacity * Subject without health insurance coverage * Exclusion period of another study or exclusion period of the French national healthy volunteer registry

Locations (1)

CHU de besançon

Besançon, France

Outcomes

Primary Outcomes

Anti-SARS-CoV-2 spike protein total IgG

Total IgG directed against anti-SARS-CoV-2 spike protein as measured by ELISA assay

Time frame: at inclusion

Secondary Outcomes

Anti-SARS-CoV-2 nucleocapsid protein total IgG

Total IgG directed against anti-SARS-CoV-2 nucleocapsid protein as measured by ELISA assay

Time frame: at inclusion

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.